Peter Diederik Jan Grootenhuis

This inventor holds 34 USPTO granted patents and 23 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Cystic Fibrosis Modulators. Top assignee: Vertex Pharmaceuticals, Inc.. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peter Diederik Jan Grootenhuis. Retrieved from https://idiyas.com/inventor/peter-diederik-jan-grootenhuis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 34 (Patent Applications = 23)

% Patents Active = 94.1

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 7 (Patent Applications = 13)

Average Co-Inventor Count = 9.6

ph-index = 16

Forward Citations = 953(Granted Patents)

Location History:

San Diego, CA (US) (2010 - 2022)
Del Mar, CA (US) (2020 - 2022)

Company Filing History:

34 out of 1,167

Vertex Pharmaceuticals, Inc.

patents

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

Cystic Fibrosis

Transmembrane Conductance Regulator

Pharmaceutical Compositions

ATP-Binding Cassette

Ion Channels

Piperidine Amides

Heterocyclic Derivatives

Modulators

Pyrazines

Oxazoles

Thiazoles

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12384762 - Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2025-08-12),

2. 12269831 - Modulators of cystic fibrosis transmembrane conductance regulator (2025-04-08),

3. 12168009 - Modulators of cystic fibrosis transmembrane conductance regulator (2024-12-17),

4. 11453655 - Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2022-09-27),

5. 11426407 - Modulators of cystic fibrosis transmembrane conductance regulator (2022-08-30),

6. 11414439 - Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2022-08-16),

7. 10987348 - Modulators of ATP-binding cassette transporters (2021-04-27),

8. 10793547 - Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2020-10-06),

9. 10758534 - Modulators of cystic fibrosis transmembrane conductance regulator (2020-09-01),

10. 10738030 - Modulators of cystic fibrosis transmembrane conductance regulator (2020-08-11),

11. 10258624 - Modulators of cystic fibrosis transmembrane conductance regulator (2019-04-16),

12. 10233191 - Fused piperidine amides as modulators of ion channels (2019-03-19),

13. 10022352 - Modulators of ATP-binding cassette transporters (2018-07-17),

14. 9974781 - Modulators of ATP-binding cassette transporters (2018-05-22),

15. 9782408 - Modulators of cystic fibrosis transmembrane conductance regulator (2017-10-10),

Title: Innovator Spotlight: Peter Diederik Jan Grootenhuis

Introduction: Meet Peter Diederik Jan Grootenhuis, a prolific inventor based in San Diego, CA, with an impressive portfolio of 31 patents. Grootenhuis is renowned for his groundbreaking work in developing modulators of the cystic fibrosis transmembrane conductance regulator.

Latest Patents: One of Grootenhuis's recent patents includes the development of a modulator of the cystic fibrosis transmembrane conductance regulator. This patent encompasses pharmaceutical compositions, methods of treatment, and a unique process for producing the modulator. The compounds disclosed in this patent have shown promising results in treating cystic fibrosis and related diseases.

Career Highlights: Peter Diederik Jan Grootenhuis is a key figure at Vertex Pharmaceuticals, Inc., a leading pharmaceutical company at the forefront of innovative medical solutions. His contributions have significantly advanced the field of cystic fibrosis treatment, earning him recognition as a trailblazer in the industry.

Collaborations: Grootenhuis's impactful work has been enriched by collaborations with esteemed colleagues such as Mark Thomas Miller and Jason McCartney. Together, they have synergized their expertise to push the boundaries of medical research and develop life-changing therapies for patients.

Conclusion: In conclusion, Peter Diederik Jan Grootenhuis stands as a visionary inventor who continues to revolutionize the treatment of cystic fibrosis. His dedication to scientific innovation and collaborative spirit underscores his influential role in shaping the future of medicine.

Profile summary based on public USPTO records.